Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DP2Z0X
|
|||
| Drug Name |
Sasanlimab
|
|||
| Synonyms |
PF-06801591
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Non-muscle invasive bladder cancer [ICD-11: 2C94; ICD-10: C67, C67.9; ICD-9: 188] | Phase 3 | [1] | |
| Company |
Pfizer
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Programmed cell death protein 1 (PD-1) | Target Info | . | [2] |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| T cell receptor signaling pathway | ||||
| Reactome | PD-1 signaling | |||
| WikiPathways | T-Cell Receptor and Co-stimulatory Signaling | |||
| Costimulation by the CD28 family | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04165317) Study of Sasanlimab (PF-06801591) in Combination With Bacillus Calmette-Guerin (BCG) in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (CREST). U.S. National Institutes of Health. | |||
| REF 2 | Pharmacologic Properties and Preclinical Activity of Sasanlimab, A High-affinity Engineered Anti-Human PD-1 Antibody. Mol Cancer Ther. 2020 Oct;19(10):2105-2116. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.